SynthesisJournal of gastrointestinal cancer2026
Clinical and Epidemiologic Characteristics of Patients with Hepatocellular Carcinoma in South Asia: A Systematic Review and Meta-analysis.
Synthesis in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsComprehensive data on hepatocellular carcinoma (HCC) in South Asia remains limited. This systematic review and meta-analysis describe characteristics and risk factors associated with HCC among South Asian adults.
methodsWe surveyed PubMed/MEDLINE and Scopus for articles on descriptive studies on HCC in South Asia. The search terms included "hepatocellular carcinoma" AND "South Asia" AND individual South Asian countries ("Afghanistan", "Bangladesh", "Bhutan", "India", "Maldives", "Nepal", "Pakistan", and "Sri Lanka"). We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. All the selected studies fulfilled the diagnostic criteria for HCC. We used the Joanna Briggs Institute Critical Appraisal Checklist for Prevalence Studies to assess the quality of the studies. The data extracted from the selected studies were used to produce pooled estimates for the HCC characteristics and associations.
resultsOnly 28 publications (Bangladesh-1, India-16, Nepal-2, Pakistan-7, Sri Lanka-2) were selected. HCC is more common in men (81%) and is diagnosed around the age of 56 years in South Asia. Most cases (82%) develop in patients with cirrhosis. Chronic HBV infection (27%) is the leading risk factor, followed by chronic HCV infection (21%) and alcohol-related liver disease (21%). HCC is often detected at advanced stages (BCLC-B 29% and BCCL-C 43%), presenting as large (5-10 cm in 57%), single tumours with frequent blood vessel involvement (39%). Sorafenib (33%) is the most common treatment, followed by TACE (22%). The median overall survival is 17.3 months.
conclusionsHepatocellular carcinoma occurs more often among males and in the sixth decade of life. Most cases develop in patients with cirrhosis due to HBV, HCV or alcohol excess. Hepatocellular carcinoma presents at an advanced stage as an aggressive disease, with a median overall survival of one and a half years in South Asia.
Indexed as
Identifiers
41689607What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.